Neuren Pharmaceuticals (ASX:NEU): H1FY26 Earnings, DAYBUE Royalties and Clinical Development

Aditi Sarkar

26 October 2026 03:57 PM AEDT

Neuren Pharmaceuticals (ASX:NEU): H1FY26 Earnings, DAYBUE Royalties and Clinical Development

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Neuren Pharmaceuticals (ASX:NEU) recorded H1FY26 total income of AUD 42.75mn, up 8% YoY.
H1FY26 net profit fell to AUD 4.85mn from AUD 15.03mn as research expenditure increased.
DAYBUE royalty income reached USD 23.3mn in H1FY26, up 29% YoY in US dollar terms.
A September 2026 notice of allowance concerned US trofinetide patent protection potentially extending to March 2041.

Neuren Pharmaceuticals Limited (ASX:NEU) develops medicines for neurological disorders linked to genetic abnormalities or brain injury, while earning royalties from licensed trofinetide products for Rett syndrome. On 26 October 2026, Neuren Pharmaceuticals (ASX:NEU) was quoted at AUD 18.82, down 3.88% for the session. The company’s H1FY26 results showed increasing DAYBUE royalty income alongside higher clinical-development expenditure, while its recent updates covered US patent protection and the ongoing NNZ-2591 trial programme.

Company Business

Neuren Pharmaceuticals (ASX:NEU) operates through commercial products and research and development. Its commercial income comes principally from an exclusive worldwide licence of trofinetide, marketed as DAYBUE and DAYBUE STIX in the United States for Rett syndrome. Its licensee manages commercial sales and relevant regional registration activities, while Neuren receives royalties and may earn contractual milestone payments.

The research portfolio centres on NNZ-2591, also called ercanetide, an investigational oral treatment being studied for rare neurodevelopmental disorders. Its development includes Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome, as well as research into hypoxic ischaemic encephalopathy. Neuren is incorporated in New Zealand and based in Melbourne, with clinical and commercial exposure extending beyond Australia.

Recent Development

In September 2026, Neuren Pharmaceuticals (ASX:NEU) disclosed that the US Patent and Trademark Office had issued a Notice of Allowance for a patent application concerning weight-banded dosing of trofinetide. The company stated that, following issuance and including paediatric exclusivity, the patent was expected to protect the relevant US dosing regimen through 28 March 2041. The notice related to an application proceeding through administrative steps, rather than a newly issued patent at the announcement date.

In August 2026, Neuren reported that the European Commission had authorised DAYBU for Rett syndrome in eligible adults and children. A commercial launch in Germany was anticipated in early 4QCY26. The company also identified results from a Japanese trofinetide trial as an upcoming event, with a regulatory submission contemplated for 2027.

For NNZ-2591, the Koala Phase 3 trial in Phelan-McDermid syndrome was enrolling at 15 sites in the United States and Canada in August, while eight sites had been activated for its open-label extension. A late-October FDA meeting was scheduled to discuss a clinical-development pathway in Pitt Hopkins syndrome. The outcome of that meeting had not been established by these disclosures.

Financial Performance and Sector Context

Neuren Pharmaceuticals (ASX:NEU) reported H1FY26 total income of AUD 42.75mn, compared with AUD 39.72mn in H1FY25, an increase of 8% YoY. Revenue from contracts with customers rose to AUD 33.16mn from AUD 28.28mn. DAYBUE royalty income was USD 23.3mn, up 29% YoY in US dollar terms, reflecting higher net sales reported by its commercial licensee.

Research and development expenditure increased to AUD 27.42mn from AUD 14.90mn, largely associated with progress on the Phase 3 programme. Net profit after tax consequently declined to AUD 4.85mn from AUD 15.03mn. The group also recognised AUD 4.71mn in fair-value losses on financial derivatives, compared with AUD 2.62mn a year earlier.

Cash and short-term investments were AUD 286.54mn at 30 June 2026, compared with AUD 296.12mn at 31 December 2025. H1FY26 net operating cash inflow was AUD 8.00mn, against AUD 128.31mn in H1FY25, when licence receipts included unusually large milestone-related amounts. The commercial outlook is influenced by Rett syndrome treatment access, patient uptake, additional jurisdictional approvals and the contractual royalty structure.

Risks to Consider

Neuren Pharmaceuticals (ASX:NEU) faces clinical-development and regulatory risks for NNZ-2591, including trial recruitment, study outcomes, manufacturing and regulatory review. Trofinetide royalties depend on commercial execution by its licensee and on treatment uptake. Currency movements can affect AUD-reported earnings, while research costs may fluctuate with the timing and extent of clinical programmes. Patent applications and international commercial launches also involve execution and legal uncertainty.

What to Watch Next

Near-term monitoring points for Neuren Pharmaceuticals (ASX:NEU) include updates from the Pitt Hopkins regulatory discussion, recruitment and progress in the Koala Phase 3 study, the Japanese trofinetide trial readout and the timing of European commercialisation. Subsequent royalty disclosures and cash-flow reports will indicate how commercial receipts compare with clinical-development expenditure.

Key Insights

H1FY26 combined increased trofinetide revenue with higher NNZ-2591 trial costs, reducing reported profit despite growth in overall income. The September patent update addressed potential US protection for a trofinetide dosing regimen. Neuren’s next reported milestones will concern international commercial activities, clinical execution and the pace of royalty receipts relative to research spending.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.